Verified discoveries, trials, and approvals for this cancer type. Every story separates evidence strength, regulatory status, and guideline position.
In the randomized, phase 3 IMvigor011 trial, atezolizumab reduced the risk of disease recurrence or death by 36% and the risk of death by 41% compared with placebo, specifically in…
Primary source cited
Last reviewed
In the randomized, phase 3 AMBASSADOR trial, adjuvant pembrolizumab after radical surgery significantly extended disease-free survival compared with observation alone in patients with high-risk muscle-invasive or locally advanced urothelial carcinoma.…
Primary source cited
Last reviewed
In the randomized, phase 3 IMvigor011 trial, atezolizumab reduced the risk of disease recurrence or death by 36% and the risk of death by 41% compared with placebo, specifically in…
Primary source cited
Last reviewed
In the randomized, phase 3 AMBASSADOR trial, adjuvant pembrolizumab after radical surgery significantly extended disease-free survival compared with observation alone in patients with high-risk muscle-invasive or locally advanced urothelial carcinoma.…
Primary source cited
Last reviewed
Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
AMBASSADOR/A031501 trial primary results: adjuvant pembrolizumab in muscle-invasive urothelial carcinoma (NEJM). DOI 10.1056/NEJMoa2401726, PMID 39282902.
Eligibility varies — review trial criteria.
Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.
Adjuvant Atezolizumab Guided by Circulating Tumor DNA in Muscle-Invasive Bladder Cancer (New England Journal of Medicine). DOI 10.1056/NEJMoa2511885, PMID 41124204.
Applies to the exact indication stated.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.